Truncated	O
galectin	O
-	O
3	O
inhibits	O
tumor	B-Cancer
growth	O
and	O
metastasis	O
in	O
orthotopic	O
nude	O
mouse	O
model	O
of	O
human	O
breast	B-Cancer
cancer	I-Cancer
.	O

PURPOSE	O
:	O
The	O
goal	O
of	O
this	O
research	O
was	O
to	O
evaluate	O
a	O
potential	O
therapeutic	O
agent	O
for	O
breast	B-Cancer
cancer	I-Cancer
based	O
on	O
galectin	O
-	O
3	O
that	O
has	O
been	O
implicated	O
in	O
tumorigenicity	O
and	O
metastasis	O
of	O
breast	B-Cancer
cancer	I-Cancer
.	O

The	O
hypothesis	O
was	O
that	O
therapy	O
with	O
NH	O
(	O
2	O
)	O
-	O
terminally	O
truncated	O
form	O
of	O
galectin	O
-	O
3	O
(	O
galectin	O
-	O
3C	O
)	O
will	O
be	O
efficacious	O
for	O
reduction	O
in	O
tumor	B-Cancer
growth	O
and	O
for	O
inhibition	O
of	O
metastases	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Recombinant	O
human	O
galectin	O
-	O
3	O
was	O
produced	O
in	O
Escherichia	O
coli	O
from	O
which	O
galectin	O
-	O
3C	O
was	O
derived	O
by	O
collagenase	O
enzyme	O
digestion	O
.	O

Toxicity	O
,	O
pharmacokinetic	O
,	O
and	O
organ	B-Organ
biodistribution	O
studies	O
were	O
performed	O
in	O
nude	O
mice	O
.	O

For	O
efficacy	O
studies	O
,	O
nude	O
mice	O
bearing	O
orthotopically	O
implanted	O
tumors	B-Cancer
derived	O
from	O
breast	B-Cell
cancer	I-Cell
cell	I-Cell
line	I-Cell
MDA	I-Cell
-	I-Cell
MB	I-Cell
-	I-Cell
435	I-Cell
were	O
treated	O
with	O
galectin	O
-	O
3C	O
or	O
a	O
vehicle	O
control	O
i	O
.	O
m	O
.	O
twice	O
daily	O
for	O
90	O
days	O
.	O

RESULTS	O
:	O
The	O
maximum	O
tolerated	O
dose	O
of	O
galectin	O
-	O
3C	O
in	O
nude	O
mice	O
was	O
determined	O
to	O
be	O
>	O
125	O
mg	O
/	O
kg	O
without	O
overt	O
adverse	O
effects	O
.	O

The	O
elimination	O
half	O
-	O
life	O
when	O
administered	O
i	O
.	O
m	O
.	O
was	O
found	O
to	O
be	O
3	O
.	O
0	O
h	O
in	O
the	O
serum	B-Organism_substance
and	O
4	O
.	O
3	O
h	O
in	O
the	O
cellular	B-Cell
fraction	O
of	O
the	O
blood	B-Organism_substance
.	O

Organ	O
biodistribution	O
studies	O
revealed	O
that	O
galectin	O
-	O
3C	O
localized	O
in	O
the	O
liver	B-Organ
,	O
kidneys	B-Organ
,	O
and	O
spleen	B-Organ
but	O
not	O
in	O
the	O
heart	B-Organ
or	O
lungs	B-Organ
.	O

We	O
found	O
that	O
the	O
mean	O
tumor	B-Cancer
volumes	O
and	O
weights	O
were	O
statistically	O
significantly	O
less	O
in	O
mice	O
treated	O
with	O
galectin	O
-	O
3C	O
compared	O
with	O
control	O
mice	O
,	O
and	O
that	O
fewer	O
numbers	O
of	O
mice	O
exhibited	O
lymph	B-Cancer
node	I-Cancer
metastases	I-Cancer
in	O
the	O
treated	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
:	O
Galectin	O
-	O
3C	O
is	O
not	O
overtly	O
toxic	O
,	O
and	O
is	O
efficacious	O
in	O
reducing	O
metastases	B-Cancer
and	O
tumor	B-Cancer
volumes	O
and	O
weights	O
in	O
primary	B-Cancer
tumors	I-Cancer
in	O
an	O
orthotopic	O
nude	O
mouse	O
model	O
of	O
human	O
breast	B-Cancer
cancer	I-Cancer
.	O

